Phase 2 N=17 Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
Limbal Stem Cell Deficiency
Primary: Primary Safety Events of Interest — 1; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Metastatic or Unresectable Melanoma
Primary: Best Overall Response as Defined by RECIST 1.1 Criteria — 0 Participants
Phase 2 N=156 UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Malignant Melanoma
Primary: PFS Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (by Blinded Independent Central Review (BICR) — 35; 34 Participants — p=0.845
Phase 2 N=21 Stem Cells in Rapidly Evolving Active Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Adverse Events Assessed by CTCAE v4.0 — 5; 0 total events
Phase 2 N=155 Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
Non Small Cell Lung Cancer Metastatic
Primary: Progression Free Survival (PFS) — 15.4; 12.3 months — p=0.84
Phase 2 N=97 Onsite Buprenorphine Treatment at Syringe Exchange Programs
Opiate Addiction
Primary: Buprenorphine Engagement — 19; 19 Participants — p=0.94
Phase 2 N=4 Vigabatrin and Insulin Sensitivity
NAFLD · Obesity
Primary: Insulin Sensitivity — 6.82 mg/kg FFM/min
Phase 2 N=31 Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Invasive Aspergillosis
Primary: Percentage of Participants Who Experience One or More Treatment-related Adverse Events (AEs) — 14.3; 29.4 Percentage of participants
Phase 2 N=13 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…
Phase 2 N=154 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme · Glioblastoma · Malignant Glioma
Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196
Phase 2 N=185 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants With Treatment-Emergent Adverse Events — 34; 31; 30; 11 participants
Phase 2 N=37 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Phase 2 N=190 A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
Narcolepsy
Primary: Epworth Sleepiness Scale — -5.1; -5.6; -3.3 score on a scale — p=0.024
Phase 2 N=269 Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
Group B Streptococcal Infection
Primary: Concentrations of Immunoglobulin (Ig) G Antibodies Specific to the AlpN Proteins in μg/mL in Cord Blood From Each Baby — 11.12; 5.52; 7.95; 3.51 μg/mL
Phase 2 N=40 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Carcinoma, Squamous Cell of Head and Neck · Oropharynx Squamous Cell Carcinoma
Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants